BioSpace News Archive

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata,” “us,” “our,” or the “Company”), today announced that the company has received an equity investment from the Cystic Fibrosis Foundation (“CF Foundation”) with participation from Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (collectively, “Innoviva”).

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2021 financial results on Wednesday, November 3, 2021 after the markets close.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the first quarter ended September 30, 2021, and an update on its pipeline of late-stage product candidates.

Exosystems, an artificial intelligence -based digital healthcare company and a member of Born2Global Centre, has succeeded in attracting Series A funding worth USD 3.9 million from SBI Investment, Laguna Investment, and Korea Technology Finance Corporation.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it priced an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of $25.00 per share.

Biofrontera Inc. (“Biofrontera” or the “Company”) (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the pricing of its underwritten initial public offering of 3,600,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $5.00.

Aura Biosciences, Inc. (“Aura”), a clinical-stage oncology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the pricing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced the pricing of its initial public offering of 7,800,000 shares of its common stock at a public offering price of $12.00 per share, for total gross proceeds of $93.6 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Entrada Therapeutics, Inc., a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle therapeutics as a new class of medicines and aiming to become the world’s foremost intracellular therapeutics company, announced the pricing of its upsized initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share.